noodls browser compatibility check

The security settings of your browser are blocking the execution of scripts.

To use noodls, javascript support must be enabled. Please change your browser's security settings to enable javascript.

If you have changed your browser's security settings, you can click here.

related announcements

News

Steve Scalise

Scalise: Democrats cheer 'No Kings' protests, but let shutdown[...]
Amazon.com Inc.

Jody’s Inc. Recalls Cabot Creamery Sea Salt Caramel Cheddar Popcorn Due[...]
Wyoming Department of[...]

Public Notice: Public Meeting, City of Sheridan, WY, Sheridan Landfill[...]

Healthcare

AstraZeneca Pharmaceuticals LP

10/18/2025 | Press release | Distributed by Public on 10/18/2025 08:44

ENHERTU® (fam-trastuzumab deruxtecan-nxki) followed by THP before surgery resulted in a pathologic complete response in 67% of patients with high-risk HER2-positive early-stage[...]

Read this content

Click here to read the original version at the source's official website. The text of this article is not available at the moment.

AstraZeneca Pharmaceuticals LP published this content on October 18, 2025, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 18, 2025 at 14:44 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]

Back